# NCT03553836 (NCT03553836)

> Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03553836
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Melanoma
- Interventions: Pembrolizumab; Placebo
- Enrollment: 976
- Primary outcome: Recurrence-free Survival (RFS)

## Commentary we found

- Podcasts: 26
- YouTube: 17
- X threads: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03553836

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03553836", "email": "<work email>"}; the inbox owner confirms by the emailed link.